Nitric oxide in the pulmonary vasculature.
Homeostasis in the pulmonary vasculature is maintained by the actions of vasoactive compounds, including nitric oxide (NO). NO is critical for normal development of the pulmonary vasculature and continues to mediate normal vasoregulation in adulthood. Loss of NO bioavailability is one component of the endothelial dysfunction and vascular pathology found in pulmonary hypertension (PH). A broad research effort continues to expand our understanding of the control of NO production and NO signaling and has generated novel theories on the importance of pulmonary NO production in the control of the systemic vasculature. This understanding has led to exciting developments in our ability to treat PH, including inhaled NO and phosphodiesterase inhibitors, and to several promising directions for future therapies using nitric oxide-donor compounds, stimulators of soluble guanylate cyclase, progenitor cells expressing NO synthase (NOS), and NOS gene manipulation.
Coggins
Matthew P
MP
Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. mcoggins@partners.org
Bloch
Kenneth D
KD
D000818:Animals; D006706:Homeostasis; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology* / Q000628:therapy; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism* / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000502:physiology*; D051381:Rats; D015398:Signal Transduction / Q000502:physiology
D009569:Nitric Oxide